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Abstract: Indications for remediastinoscopy include recurrent and
second primary lung cancer, an inadequate first procedure, lung cancer
occurring after an unrelated disease such as lymphoma, and restaging
after induction therapy. Nowadays, restaging is the most frequent
indication for remediastinoscopy. Only patients with proven mediasti-
nal downstaging will benefit from a subsequent surgical resection. In
contrast to imaging or functional studies, remediastinoscopy provides
pathologic evidence of response after induction therapy. Although
technically more challenging than a first procedure, remediastinoscopy
can select patients for subsequent thoracotomy and provides prognostic
information. In most recent series, sensitivity of remediastinoscopy is
higher than 70% with an accuracy of approximately 85%. Survival also
depends on the findings at remediastinoscopy, with patients with per-
sisting mediastinal involvement having a poor prognosis. An alternative
approach consists of the use of minimally invasive staging procedures
as endobronchial or endoscopic esophageal ultrasonography to obtain
initial proof of mediastinal nodal involvement. Mediastinoscopy is
subsequently performed after induction therapy to evaluate response. In
this way, a technically more difficult remediastinoscopy can be avoided.
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ing, Repeat mediastinoscopy.
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INDICATIONS
The different indications for repeat or remediastinos-
copy (reMS) are listed in Table 1. Currently reMS is mostly
performed for restaging of non-small cell lung cancer
(NSCLC) after induction chemotherapy or chemoradiother-
apy. Important prognostic factors after induction therapy for
locally advanced NSCLC include complete surgical resection
and downstaging of mediastinal lymph nodes.1 Only patients
with mediastinal downstaging will benefit from a subsequent
surgical resection, especially when a lobectomy can be per-
formed. In contrast to imaging or functional studies, reMS
offers the advantage of providing pathologic evidence of
response after induction therapy. In this way, it is a valuable
tool to select patients for surgical resection.
TECHNIQUE
Shortly after the introduction of mediastinoscopy, redo
procedures were considered technically impossible due to the
scar tissue developing after the first intervention. However, in
subsequent years, reMS was found to be technically feasible
also after induction therapy.2–4 To perform a reMS, we prefer
a classic, regular mediastinoscope for its small size and
preservation of a three-dimensional view when looking through
it.5 The procedure is performed under general anesthesia with
endotracheal intubation. The transverse scar of the initial medi-
astinoscopy is reopened. Usually the strap muscles are fibrotic,
and sharp dissection is necessary to reach the pretracheal plane.
The innominate artery can be very adherent to the trachea, which
represents a major danger point. For this reason, the pretracheal
plane usually cannot be safely developed. In most cases, a tunnel
can be created by blunt dissection on the left paratracheal side.2
Underneath the aortic arch, dissection can be continued in the
pretracheal plane until the subcarinal nodes are reached. Bleed-
ing is usually treated by packing or electrocoagulation. In severe
cases, sternotomy or thoracotomy are indicated, depending on
the precise site of hemorrhage.
RESULTS
Our initial results with reMS in general were reported
in 1998.2 In a subsequent series, 27 patients undergoing reMS
after induction therapy were analyzed, showing that reMS is
feasible and can allow selection of patients for subsequent
therapy.6 In a recent update, survival was also analyzed.7 In
the latter series, sensitivity of reMS was 71%, specificity
100%, and accuracy 84%. Follow-up was complete in all
patients. Median survival time for the whole group was 21
months, 7 months for patients with a positive reMS, 41
months for patients with a negative reMS, and 24 months for
patients with a false-negative reMS where only a minimal
tumor bulk was present.7 The difference between positive and
negative reMS was highly significant (p  0.003).
Results of other recent series of reMS after induction
therapy are summarized in Table 2.4,7–10 The largest series
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TABLE 1. Indications for Remediastinoscopy
1. Recurrent lung cancer
2. Metachronous second primary lung cancer
3. Inadequate first procedure (sampling error)
4. Lung cancer occurring after unrelated disease (e.g., lymphoma,
sarcoidosis, other granulomatous disease)
5. Restaging of lung cancer after induction therapy
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was reported by Stamatis et al.4 in 2005, who described a total
of 279 reMS, of which 165 were performed after induction
chemoradiotherapy.
In all series, the sensitivity of reMS was higher than
70% except for the prospective series reported by De Leyn et
al.10 In this study, integrated positron emission tomography
(PET)–computed tomography was compared with reMS in
30 patients. The sensitivity of reMS was only 29% with an
accuracy of 60%. This low sensitivity is largely explained by
the fact that biopsy of the subcarinal nodes (level 7) was not
adequately performed in 20 patients (67%). A possible ex-
planation could be the use of a videomediastinoscope for the
initial and redo procedure.5 The videomediastinoscope is
larger than the classic mediastinoscope, the latter being more
easily introduced in a narrow space as the subcarinal region.
Moreover, when looking at the monitor screen during video-
mediastinoscopy, the three-dimensional view is lost.
IMPLICATIONS FOR CLINICAL PRACTICE
There are several indications for reMS (Table 1). At
present, it is mostly used for restaging after induction therapy.
Precise pathologic restaging is important as persisting medi-
astinal nodal involvement heralds a poor prognosis. Nonin-
vasive imaging techniques such as computed tomography and
magnetic resonance imaging are not accurate enough for
mediastinal restaging. Functional metabolic studies such as
PET provide additional information, but there are conflicting
data regarding the use of PET or integrated PET-computed
tomography for re-evaluation of the mediastinum after induc-
tion therapy. Moreover, PET is expensive and not readily
available, and its precise timing during or after induction
therapy has not been established.
Although the sensitivity and accuracy of reMS are
lower than after the first procedure, it is a valuable tool for
restaging as it provides pathologic proof of mediastinal
downstaging. In this regard, reMS is useful to determine
subsequent treatment. Comparing our early and late results,
sensitivity did not increase over time.6,7 Most false-negative
cases are due to remaining micrometastases, and it will be
difficult to eliminate these, even with increasing experience.
We did not observe any increased difficulties after induc-
tion chemoradiotherapy compared with chemotherapy alone,
although our experience is limited.6,7 In the large series reported
by Stamatis et al., all patients had induction chemoradiotherapy
and overall sensitivity was not different from that in our series.4,7
Survival also depends on the findings at reMS, with
patients with persisting mediastinal involvement having a
grim prognosis.
For those thoracic surgeons having no experience with
reMS, an alternative approach consists of the use of minimally
invasive staging procedures such as endobronchial or endo-
scopic esophageal ultrasonography to obtain a cytologic proof of
mediastinal nodal involvement. After induction therapy, patients
are subsequently restaged by mediastinoscopy. In this way, a
technically more demanding reMS can be avoided.
In summary, pathologic restaging after induction ther-
apy is mandatory. ReMS provides valuable pathologic infor-
mation after induction therapy. Results will determine sub-
sequent treatment and provide prognostic information.
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TABLE 2. Results of Remediastinoscopy after Induction Therapy
Ref. n IT % Morbidity % Mortality % Sensitivity % Specificity % Accuracy
Pitz et al.8 15 CT 0 0 71.4 100 87
Rami-Porta et al.9 24a CT 0 0 83 100 91
Stamatis et al.4 165 CT-RT 2.5 0 74 100 93
De Waele et al.7 32 CT (n  26) 3.1 0 71 100 84
CT-RT (n  6)
De Leyn et al.10 30 CT 0 0 29 100 60
a Period 1999–2003 (total series  48 patients).
n, number of patients; IT, induction therapy; CT, chemotherapy; CT-RT, chemoradiotherapy.
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